A Randomised, Controlled, Phase 1 Study in Healthy Adults to Evaluate the Immunogenicity and Safety of a Recombinant H7 Hemagglutinin Influenza Vaccine

Trial Profile

A Randomised, Controlled, Phase 1 Study in Healthy Adults to Evaluate the Immunogenicity and Safety of a Recombinant H7 Hemagglutinin Influenza Vaccine

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 May 2018

At a glance

  • Drugs PanBlok (Primary) ; ADVAX
  • Indications Influenza A virus H7N9 subtype
  • Focus Pharmacodynamics
  • Sponsors Vaxine
  • Most Recent Events

    • 04 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
    • 04 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 06 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top